|
1
|
Bertino G, Demma S, Ardiri A, Proiti M,
Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M,
Malaguarnera M, et al: Hepatocellular carcinoma: Novel molecular
targets in carcinogenesis for future therapies. BioMed Res Int.
2014:2036932014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ishikawa T: Clinical features of hepatitis
B virus-related hepatocellular carcinoma. World J Gastroenterol.
16:2463–2467. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bréchot C, Gozuacik D, Murakami Y and
Paterlini-Bréchot P: Molecular bases for the development of
hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).
Semin Cancer Biol. 10:211–231. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma S, Jiao B and Liu X, Yi H, Kong D, Gao
L, Zhao G, Yang Y and Liu X: Approach to radiation therapy in
hepatocellular carcinoma. Cancer Treat Rev. 36:157–163. 2010.
View Article : Google Scholar
|
|
5
|
Lo CM, Ngan H, Tso WK, Liu CL, Lam CM,
Poon RT, Fan ST and Wong J: Randomized controlled trial of
transarterial lipiodol chemoembolization for unresectable
hepatocellular carcinoma. Hepatology. 35:1164–1171. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam
CM and Wong J: Improving survival results after resection of
hepatocellular carcinoma: A prospective study of 377 patients over
10 years. Ann Surg. 234:63–70. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Paska AV and Hudler P: Aberrant
methylation patterns in cancer: A clinical view. Biochem Med
Zagreb. 25:161–176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Robertson KD: DNA methylation and human
disease. Nat Rev Genet. 6:597–610. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Globisch D, Münzel M, Müller M, Michalakis
S, Wagner M, Koch S, Brückl T, Biel M and Carell T: Tissue
distribution of 5-hydroxymethylcytosine and search for active
demethylation intermediates. PLoS One. 5:e153672010. View Article : Google Scholar
|
|
11
|
Ruzov A, Tsenkina Y, Serio A, Dudnakova T,
Fletcher J, Bai Y, Chebotareva T, Pells S, Hannoun Z, Sullivan G,
et al: Lineage-specific distribution of high levels of genomic
5-hydroxymethylcytosine in mammalian development. Cell Res.
21:1332–1342. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tan L and Shi YG: Tet family proteins and
5-hydroxymethylcytosine in development and disease. Development.
139:1895–1902. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Branco MR, Ficz G and Reik W: Uncovering
the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev
Genet. 13:7–13. 2011.PubMed/NCBI
|
|
14
|
Haffner MC, Chaux A, Meeker AK, Esopi DM,
Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C,
Nelson WG, et al: Global 5-hydroxymethylcytosine content is
significantly reduced in tissue stem/progenitor cell compartments
and in human cancers. Oncotarget. 2:627–637. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moribe T, Iizuka N, Miura T, Kimura N,
Tamatsukuri S, Ishitsuka H, Hamamoto Y, Sakamoto K, Tamesa T and
Oka M: Methylation of multiple genes as molecular markers for
diagnosis of a small, well-differentiated hepatocellular carcinoma.
Int J Cancer. 125:388–397. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lou C, Du Z, Yang B, Gao Y, Wang Y and
Fang S: Aberrant DNA methylation profile of hepatocellular
carcinoma and surgically resected margin. Cancer Sci. 100:996–1004.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mardis ER: Next-generation DNA sequencing
methods. Annu Rev Genomics Hum Genet. 9:387–402. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shendure J and Ji H: Next-generation DNA
sequencing. Nat Biotechnol. 26:1135–1145. 2008. View Article : Google Scholar
|
|
19
|
Shitani M, Sasaki S, Akutsu N, Takagi H,
Suzuki H, Nojima M, Yamamoto H, Tokino T, Hirata K, Imai K, et al:
Genome-wide analysis of DNA methylation identifies novel
cancer-related genes in hepatocellular carcinoma. Tumour Biol.
33:1307–1317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen J, Wang S, Zhang YJ, Wu HC, Kibriya
MG, Jasmine F, Ahsan H, Wu DP, Siegel AB, Remotti H, et al:
Exploring genome-wide DNA methylation profiles altered in
hepatocellular carcinoma using Infinium HumanMethylation 450
BeadChips. Epigenetics. 8:34–43. 2013. View Article : Google Scholar :
|
|
21
|
Iyer P, Zekri AR, Hung CW, Schiefelbein E,
Ismail K, Hablas A, Seifeldin IA and Soliman AS: Concordance of DNA
methylation pattern in plasma and tumor DNA of Egyptian
hepatocellular carcinoma patients. Exp Mol Pathol. 88:107–111.
2010. View Article : Google Scholar
|
|
22
|
Tan L, Xiong L, Xu W, Wu F, Huang N, Xu Y,
Kong L, Zheng L, Schwartz L, Shi Y, et al: Genome-wide comparison
of DNA hydroxymethylation in mouse embryonic stem cells and neural
progenitor cells by a new comparative hMeDIP-seq method. Nucleic
Acids Res. 41:e842013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jones PA and Takai D: The role of DNA
methylation in mammalian epigenetics. Science. 293:1068–1070. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen J, Wang S, Zhang YJ, Kappil MA, Chen
Wu H, Kibriya MG, Wang Q, Jasmine F, Ahsan H, Lee PH, et al:
Genome-wide aberrant DNA methylation of microRNA host genes in
hepatocellular carcinoma. Epigenetics. 7:1230–1237. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nishida N, Nishimura T, Nakai T, Chishina
H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, et
al: Genome-wide profiling of DNA methylation and tumor progression
in human hepatocellular carcinoma. Dig Dis. 32:658–663. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kudo Y, Tateishi K, Yamamoto K, Yamamoto
S, Asaoka Y, Ijichi H, Nagae G, Yoshida H, Aburatani H and Koike K:
Loss of 5-hydroxymethylcytosine is accompanied with malignant
cellular transformation. Cancer Sci. 103:670–676. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bird A: DNA methylation patterns and
epigenetic memory. Genes Dev. 16:6–21. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jones PA and Laird PW: Cancer epigenetics
comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
31
|
Jones PL, Veenstra GJ, Wade PA, Vermaak D,
Kass SU, Landsberger N, Strouboulis J and Wolffe AP: Methylated DNA
and MeCP2 recruit histone deacetylase to repress transcription. Nat
Genet. 19:187–191. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gonzalgo ML, Hayashida T, Bender CM, Pao
MM, Tsai YC, Gonzales FA, Nguyen HD, Nguyen TT and Jones PA: The
role of DNA methylation in expression of the p19/p16 locus in human
bladder cancer cell lines. Cancer Res. 58:1245–1252.
1998.PubMed/NCBI
|
|
33
|
Zhai JM, Yin XY, Hou X, Hao XY, Cai JP,
Liang LJ and Zhang LJ: Analysis of the genome-wide DNA methylation
profile of side population cells in hepatocellular carcinoma. Dig
Dis Sci. 58:1934–1947. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cairns P, Mao L, Merlo A, Lee DJ, Schwab
D, Eby Y, Tokino K, van der Riet P, Blaugrund JE and Sidransky D:
Rates of p16 (MTS1) mutations in primary tumors with 9p loss.
Science. 265:415–417. 1994. View Article : Google Scholar
|
|
35
|
Okamoto A, Demetrick DJ, Spillare EA,
Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano
M and Beach DH: Mutations and altered expression of p16INK4 in
human cancer. Proc Natl Acad Sci USA. 91:11045–11049. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rousseau E, Ruchoux MM, Scaravilli F,
Chapon F, Vinchon M, De Smet C, Godfraind C and Vikkula M: CDKN2A,
CDKN2B and p14ARF are frequently and differentially methylated in
ependymal tumours. Neuropathol Appl Neurobiol. 29:574–583. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gonzalez-Zulueta M, Bender CM, Yang AS,
Nguyen T, Beart RW, Van Tornout JM and Jones PA: Methylation of the
5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and
transformed human tissues correlates with gene silencing. Cancer
Res. 55:4531–4535. 1995.PubMed/NCBI
|
|
38
|
Colot V and Rossignol JL: Isolation of the
Ascobolus immersus spore color gene b2 and study in single cells of
gene silencing by methylation induced premeiotically. Genetics.
141:1299–1314. 1995.PubMed/NCBI
|
|
39
|
Iolascon A, Giordani L, Moretti A, Basso
G, Borriello A and Della Ragione F: Analysis of CDKN2A, CDKN2B,
CDKN2C, and cyclin Ds gene status in hepatoblastoma. Hepatology.
27:989–995. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shen J, Wang S, Zhang YJ, Kappil M, Wu HC,
Kibriya MG, Wang Q, Jasmine F, Ahsan H, Lee PH, et al: Genome-wide
DNA methylation profiles in hepatocellular carcinoma. Hepatology.
55:1799–1808. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Esteller M, Corn PG, Baylin SB and Herman
JG: A gene hypermethylation profile of human cancer. Cancer Res.
61:3225–3229. 2001.PubMed/NCBI
|
|
42
|
Kawakami K, Brabender J, Lord RV, Groshen
S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer
DG, et al: Hypermethylated APC DNA in plasma and prognosis of
patients with esophageal adenocarcinoma. J Natl Cancer Inst.
92:1805–1811. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Van De Voorde L, Speeckaert R, Van Gestel
D, Bracke M, De Neve W, Delanghe J and Speeckaert M: DNA
methylation-based biomarkers in serum of patients with breast
cancer. Mutat Res. 751:304–325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Henrique R, Ribeiro FR, Fonseca D, Hoque
MO, Carvalho AL, Costa VL, Pinto M, Oliveira J, Teixeira MR,
Sidransky D, et al: High promoter methylation levels of APC predict
poor prognosis in sextant biopsies from prostate cancer patients.
Clin Cancer Res. 13:6122–6129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nishida N, Nagasaka T, Nishimura T, Ikai
I, Boland CR and Goel A: Aberrant methylation of multiple tumor
suppressor genes in aging liver, chronic hepatitis, and
hepatocellular carcinoma. Hepatology. 47:908–918. 2008. View Article : Google Scholar
|
|
46
|
Yang B, Guo M, Herman JG and Clark DP:
Aberrant promoter methylation profiles of tumor suppressor genes in
hepatocellular carcinoma. Am J Pathol. 163:1101–1107. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fang C, Wei XM, Zeng XT, Wang FB, Weng H
and Long X: Aberrant GSTP1 promoter methylation is associated with
increased risk and advanced stage of breast cancer: A meta-analysis
of 19 case-control studies. BMC Cancer. 15:9202015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zelic R, Fiano V, Zugna D, Grasso C,
Delsedime L, Daniele L, Galliano D, Pettersson A, Gillio-Tos A,
Merletti F, et al: Global hypomethylation (LINE-1) and
gene-specific hypermethylation (GSTP1) on initial negative prostate
biopsy as markers of prostate cancer on a rebiopsy. Clin Cancer
Res. 22:984–992. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu D, Wu J, Liu M, Yin H, He J and Zhang
B: Downregulation of miRNA-30c and miR-203a is associated with
hepatitis C virus core protein-induced epithelial-mesenchymal
transition in normal hepatocytes and hepatocellular carcinoma
cells. Biochem Biophys Res Commun. 464:1215–1221. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Saberi E, Kordi-Tamandani DM, Jamali S and
Rigi-Ladiz MA: Analysis of methylation and mRNA expression status
of FADD and FAS genes in patients with oral squamous cell
carcinoma. Med Oral Patol Oral Cir Bucal. 19:e562–e568.
2014.PubMed/NCBI
|
|
51
|
Friedrich MG, Chandrasoma S, Siegmund KD,
Weisenberger DJ, Cheng JC, Toma MI, Huland H, Jones PA and Liang G:
Prognostic relevance of methylation markers in patients with
non-muscle invasive bladder carcinoma. Eur J Cancer. 41:2769–2778.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Brognard J, Zhang YW, Puto LA and Hunter
T: Cancer-associated loss-of-function mutations implicate DAPK3 as
a tumor-suppressing kinase. Cancer Res. 71:3152–3161. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Stroud H, Feng S, Morey Kinney S, Pradhan
S and Jacobsen SE: 5-Hydroxymethylcytosine is associated with
enhancers and gene bodies in human embryonic stem cells. Genome
Biol. 12:R542011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ficz G, Branco MR, Seisenberger S, Santos
F, Krueger F, Hore TA, Marques CJ, Andrews S and Reik W: Dynamic
regulation of 5-hydroxymethylcytosine in mouse ES cells and during
differentiation. Nature. 473:398–402. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ito S, D'Alessio AC, Taranova OV, Hong K,
Sowers LC and Zhang Y: Role of Tet proteins in 5mC to 5hmC
conversion, ES-cell self-renewal and inner cell mass specification.
Nature. 466:1129–1133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mlakar V, Berginc G, Volavsek M, Stor Z,
Rems M and Glavac D: Presence of activating KRAS mutations
correlates significantly with expression of tumour suppressor genes
DCN and TPM1 in colorectal cancer. BMC Cancer. 9:2822009.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nevins JR: The Rb/E2F pathway and cancer.
Hum Mol Genet. 10:699–703. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yasui K, Okamoto H, Arii S and Inazawa J:
Association of over-expressed TFDP1 with progression of
hepatocellular carcinomas. J Hum Genet. 48:609–613. 2003.
View Article : Google Scholar
|
|
59
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Pedersen PL: Tumor mitochondria and the
bioenergetics of cancer cells. Prog Exp Tumor Res. 22:190–274.
1978. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nakashima RA, Paggi MG and Pedersen PL:
Contributions of glycolysis and oxidative phosphorylation to
adenosine 5′-triphos-phate production in AS-30D hepatoma cells.
Cancer Res. 44:5702–5706. 1984.PubMed/NCBI
|
|
62
|
Levine AJ and Puzio-Kuter AM: The control
of the metabolic switch in cancers by oncogenes and tumor
suppressor genes. Science. 330:1340–1344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ulrey CL, Liu L, Andrews LG and Tollefsbol
TO: The impact of metabolism on DNA methylation. Hum Mol Genet.
14:R139–R147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hoffman RM: Altered methionine metabolism,
DNA methylation and oncogene expression in carcinogenesis. A review
and synthesis. Biochim Biophys Acta. 738:49–87. 1984.PubMed/NCBI
|
|
65
|
Chiang CP, Lang MJ, Liu BY, Wang JT, Leu
JS, Hahn LJ and Kuo MY: Expression of proliferating cell nuclear
antigen (PCNA) in oral submucous fibrosis, oral epithelial
hyperkeratosis and oral epithelial dysplasia in Taiwan. Oral Oncol.
36:353–359. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lv Q, Zhang J, Yi Y, Huang Y, Wang Y, Wang
Y and Zhang W: Proliferating cell nuclear antigen has an
association with prognosis and risks factors of cancer patients: A
systematic review. Mol Neurobiol. Nov 12–2015.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chuang LS, Ian HI, Koh TW, Ng HH, Xu G and
Li BF: Human DNA-(cytosine-5) methyltransferase-PCNA complex as a
target for p21WAF1. Science. 277:1996–2000. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Whitesell L and Lindquist SL: HSP90 and
the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Workman P and Powers MV: Chaperoning cell
death: A critical dual role for Hsp90 in small-cell lung cancer.
Nat Chem Biol. 3:455–457. 2007. View Article : Google Scholar : PubMed/NCBI
|
